Conatus Pharmaceuticals (CNAT) Misses Q3 EPS by 8c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q3 EPS of ($0.13), $0.08 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $16.06 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c